



SUVEN LIFE SCIENCES LIMITED

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2017

All amounts in Indian Rupees in lakhs

Sl. No.	Particulars	For the Quarter Ended			For the Year Ended
		30-Jun-2017	31-Mar-2017	30-Jun-2016	31-Mar-2017
		Un-audited	Audited	Un-audited	Audited
1	Revenue from operations				
	(a) Net sales/income from operations (inclusive of excise duty)	13,744.90	17,499.64	13,322.70	53,916.74
	(b) Other operating income	357.00	515.15	-	531.04
	Total Revenue from operations	14,101.90	18,014.79	13,322.70	54,447.78
2	Other Income	562.29	493.85	449.70	2,109.25
	Total Income (1+2)	14,664.19	18,508.64	13,772.40	56,557.03
3	Expenses				
	(a) Cost of materials consumed	3,683.53	4,235.36	3,985.98	15,480.66
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(227.17)	2,234.61	(36.77)	(295.94)
	(d) Employee benefits expense	1,566.22	1,453.53	1,146.96	5,064.46
	(e) Finance costs	127.01	156.82	159.56	566.58
	(f) Depreciation and amortisation expenses	519.20	718.31	480.58	2,141.31
	(g) Manufacturing expenses	2,190.37	2,531.43	1,741.04	8,157.37
	(h) Research & Development expenses	1,601.19	1,923.75	1,469.01	6,494.09
	(i) Other expenses	759.06	819.49	673.07	3,012.81
	Total expenses	10,219.41	14,073.30	9,619.43	40,621.34
4	Profit before exceptional items and tax (1+2-3)	4,444.78	4,435.34	4,152.97	15,935.69
5	Exceptional Items	-	-	-	-
6	Profit before tax (4 - 5)	4,444.78	4,435.34	4,152.97	15,935.69
7	Tax Expenses				
	(a) Current tax	1,132.77	143.47	886.31	3,275.07
	(b) Deferred tax	354.94	284.90	9.05	313.25
8	Net Profit for the period / year (6-7)	2,957.07	4,006.97	3,257.61	12,347.37
9	Other Comprehensive Income				
9.A	(i) Items that will not be reclassified to profit or loss	(3.73)	36.96	(11.30)	(14.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.29	(12.79)	-	5.15
9.B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income	(2.44)	24.17	(11.30)	(9.75)
	Total Comprehensive Income (8+9)	2,954.63	4,031.14	3,246.31	12,337.62
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):				
	a) Basic	2.32	3.17	2.55	9.69
	b) Diluted	2.32	3.17	2.55	9.69

See accompanying notes to the financial statements

SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

PARTICULARS	For the Quarter Ended			For the Year Ended
	30-Jun-2017	31-Mar-2017	30-Jun-2016	31-Mar-2017
	Un-audited	Audited	Un-audited	Audited
1 SEGMENT REVENUE				
a) Manufacturing (CRAMS)	13,330.76	17,500.16	12,766.39	51,670.07
b) Services (DDDSS)	771.14	514.63	556.31	2,777.71
c) Research & Development	-	-	-	-
Total	14,101.90	18,014.79	13,322.70	54,447.78
Less: Inter Segment Revenue	-	-	-	-
Net Sales/Income from Operations	14,101.90	18,014.79	13,322.70	54,447.78
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)				
a) Manufacturing (CRAMS)	5,782.86	6,342.38	5,596.76	21,634.85
b) Services (DDDSS)	405.25	275.68	258.68	1,476.81
c) Research & Development	(1,601.18)	(1,923.75)	(1,469.01)	(6,494.09)
TOTAL	4,586.93	4,694.31	4,386.43	16,617.57
Less: i) Finance Cost	87.11	75.01	113.26	376.38
ii) Other Un-allocable expenditure /(income), net	55.04	183.96	120.20	305.50
Total Profit Before Tax	4,444.78	4,435.34	4,152.97	15,935.69
3 SEGMENT ASSETS :				
a) Manufacturing (CRAMS)	47,190.09	43,886.93	43,126.18	43,886.93
b) Services (DDDSS)	3,511.49	2,828.60	3,700.16	2,828.60
c) Research & Development	2,540.08	2,609.60	2,423.33	2,609.60
d) Un allocated	37,517.52	38,291.82	30,681.23	38,291.82
TOTAL	90,759.18	87,616.95	79,930.90	87,616.95
4 SEGMENT LIABILITIES :				
a) Manufacturing (CRAMS)	8,830.42	8,547.86	7,764.83	8,547.86
b) Services (DDDSS)	428.06	370.23	322.33	370.23
c) Research & Development	1,873.25	1,848.18	1,590.97	1,848.18
d) Un allocated	722.22	687.23	617.21	687.23
TOTAL	11,853.95	11,453.50	10,295.34	11,453.50

Notes:

- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the period presented been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th August 2017 and the same reviewed by the Statutory Auditors.
- The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

Place: Hyderabad
Date: 14th August, 2017

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver



SUVEN LIFE SCIENCES LTD

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor,
Road No. 5, Avenue 7, Banjara Hills, 500 034, Telangana, India. CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvен.com website: www.suven.com

EXTRACT OF STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2017

Sl. No.	Particulars	Rs. In lakhs			
		Quarter ending 30/06/2017 Un-audited	Quarter ending 31/03/2017 Audited	Quarter ending 30/06/2016 Un-audited	Year ended 31/03/2017 Audited
1	Total income from operations	14,101.90	18,014.79	13,322.70	54,447.78
2	Net profit /(loss) for the period (before tax, exceptional and/or extraordinary items)	4,444.78	4,435.34	4,152.97	15,935.69
3	Net profit /(loss) for the period before tax (after exceptional and/or extraordinary items)	4,444.78	4,435.34	4,152.97	15,935.69
4	Net profit /(loss) for the period After tax (after exceptional and/or extraordinary items)	2,957.07	4,006.97	3,257.61	12,347.37
5	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)]	2,954.63	4,031.14	3,246.31	12,337.62
6	Equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
7	Reserves (Excluding Revaluation Reserve) as shown in the audited balance sheet of previous year:	71,880.10			
8	Earnings Per Share (of Rs. 1.00/- each) (For continuing and discontinued operations) -				
	1. Basic	2.32	3.17	2.55	9.69
	2. Diluted	2.32	3.17	2.55	9.69

Notes:

- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suven.com.
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the period presented been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- The above results were reviewed by the Audit Committee of the Board and thereafter approved by the Board of Directors' at their Meeting held on 14th August, 2017 and the same reviewed by the statutory auditors.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place: Hyderabad
Date: 14th August, 2017